AE Wealth Management LLC Buys 89 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AE Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 19.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 547 shares of the biopharmaceutical company’s stock after acquiring an additional 89 shares during the quarter. AE Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $575,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the stock. West Paces Advisors Inc. lifted its position in Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares during the last quarter. Stephens Consulting LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $26,000. Sachetta LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $28,000. Finally, Lynx Investment Advisory acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $33,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 0.9 %

Shares of NASDAQ REGN opened at $1,039.96 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The firm’s 50-day moving average is $1,129.87 and its 200-day moving average is $1,033.99. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $114.59 billion, a PE ratio of 30.60, a price-to-earnings-growth ratio of 3.72 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter in the prior year, the firm posted $8.79 earnings per share. The company’s quarterly revenue was up 12.3% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. BMO Capital Markets reiterated an “outperform” rating and set a $1,300.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Royal Bank of Canada lowered their price target on Regeneron Pharmaceuticals from $1,282.00 to $1,252.00 and set an “outperform” rating on the stock in a research report on Tuesday. Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Finally, Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $1,118.62.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the transaction, the director now owns 17,882 shares in the company, valued at $18,941,329.68. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The disclosure for this sale can be found here. Insiders have sold 9,270 shares of company stock worth $10,695,833 in the last ninety days. Company insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.